Log in to search using one of your social media accounts:


Ixazomib (Ninlaro) combination rejected for multiple myeloma in second draft guidance

The National Institute for Health and Care Excellence  (NICE) has again rejected ixazomib (Ninlaro) in combination with lenalidomide and dexamethasone (IRd) for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more previous therapies.
Source: The Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research

Related Links:

More News: Dexamethasone | Drugs & Pharmacology | Myeloma | National Institute for Health and Clinical Excelle | Revlimid